Issuer readies rare life sciences securitization

A business development company that specializes in making loans to venture capital backed life sciences and technology companies is in the market this week with a $200m securitization.

  • By Max Adams
  • 17 Oct 2018
Hercules Capital is marketing Hercules Capital Funding Trust 2018-1, a single tranche securitization backed by 36 loans. Of the pool of obligors in the deal, 62.9% are companies working in life sciences such as drug discovery and development and drug delivery, and 37.1% are technology focused companies working ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

GlobalCapital European securitization league table

Rank Lead Manager/Arranger Total Volume $m No. of Deals Share % by Volume
1 BNP Paribas 15,084 31 17.18
2 Bank of America Merrill Lynch (BAML) 9,637 29 10.97
3 Citi 8,093 21 9.22
4 Lloyds Bank 7,329 24 8.35
5 JP Morgan 6,580 10 7.49

Bookrunners of Global Structured Finance

Rank Lead Manager Amount $m No of issues Share %
  • Last updated
  • Today
1 Citi 128,864.18 374 11.17%
2 Bank of America Merrill Lynch 102,984.87 299 8.93%
3 JPMorgan 101,325.97 295 8.78%
4 Wells Fargo Securities 91,373.90 263 7.92%
5 Credit Suisse 76,082.53 203 6.60%